Humana Inc

Humana Inc(HUM)股票分析

$432.200

+4.841 (+1.12%)收盘时

Loading chart…
最高
437.705
开盘
430.000
成交量加权均价
433.12
成交量
1.04M
市值
43.74B
最低
429.440
成交额
452.00M
企业价值/息税折旧摊销前利润(TTM)
8.75

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.

AI 分析 of Humana Inc (HUM)

买入

Humana Inc is a strong buy right now due to its recent surge of 13% following an upgrade in its Medicare Advantage rating, which positions 95% of its members in plans rated 4 stars or higher. The forward P/E ratio of 24.33 indicates potential for growth, and analysts have set price targets as high as $596, suggesting significant upside from the current price of $431.87. The main risk is the recent high RSI of 75.14, indicating the stock may be overbought in the short term, but the long-term outlook remains positive.

分析师评级(19)

-32.81% 下跌空间
买入
12 买入
7 持有
0 卖出
当前: 432.20
最低
231.00
平均
290.39
最高
344.00

UBS

2026-10-12

目标价

$495

中性

Oppenheimer

2026-10-12

目标价

$525

跑赢大盘

Truist

2026-10-12

目标价

$475

持有

Raymond James

2026-10-12

目标价

$520

跑赢大盘

Oppenheimer

2026-10-09

目标价

$475

跑赢大盘

估值指标

Humana Inc(HUM)当前预期市盈率为 24.33,5 年平均预期市盈率为 20.21。

预期市盈率

合理
5 年均值 P/E
20.21
当前P/E
24.33
高估
26.13
低估
14.30

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
10.63
当前EV/EBITDA
8.75
高估
14.54
低估
6.73

预期市销率

合理
5 年均值 P/S
0.42
当前P/S
0.30
高估
0.59
低估
0.24

Alphio AI 对 HUM 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%HUM

$253.64

情景价格

基

基准

基准 · 50%HUM

$209.60

情景价格

悲

悲观

悲观 · 25%HUM

$179.91

情景价格

持有 HUM 的大户

B

Braidwell LP

+ 持有HUMTMO

+19.42%

3个月收益率

A

ARGA Investment Management, LLC

+ 持有HUM

+12.90%

3个月收益率

H

Hotchkis and Wiley Capital Management, LLC

+ 持有HUM

+8.90%

3个月收益率

T

Tidal Investments LLC

+ 持有HUM

+8.50%

3个月收益率

P

PDT Partners, LLC

+ 持有HUM

+7.12%

3个月收益率

P

Pzena Investment Management, Inc.

+ 持有HUMSTX

+6.68%

3个月收益率

事件时间线

2026-10-13 (ET)

06:30:00

Humana Forms New Joint Venture with BlackRock

2026-10-09 (ET)

16:30:00

Trump Says U.S. Will Not Strike Iran, Oil Pulls Back

12:30:00

Humana Stock Rises 12.8% to $436.60

12:00:00

Tech Stock Rebound Boosts Major Averages

10:30:00

Humana Stock Rises 14.7% to $443.99

资讯

HUM 常见问题 —— 由 Alphio AI 解答

Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Humana Inc is a strong buy right now due to its recent surge of 13% following an upgrade in its Medicare Advantage rating, which positions 95% of its members in plans rated 4 stars or higher. The forward P/E ratio of 24.33 indicates potential for growth, and analysts have set price targets as high as $596, suggesting significant upside from the current price of $431.87. The main risk is the recent high RSI of 75.14, indicating the stock may be overbought in the short term, but the long-term outlook remains positive.

19 analysts cover HUM: 12 rate it Buy, 7 Hold and 0 Sell. The average price target is 290.39.

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易